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Abstract
Deferoxamine (DFO) therapy is associated with improved survival of thalas-
semia patients, and yet cardiac disease remains the main cause of death. 
Deferiprone (L1) is currently one of the orally active chelating agents used 
as an alternative to DFO. Both DFO and L1 have demonstrated their ability 
to normalize cardiac function in patients with iron-induced cardiac disease. 
Some evidence indicates that L1 is more effective than DFO in cardiac iron 
removal. Our ability to detect and manage the cardiac complications of tha-
lassemia has also improved dramatically over the last 7 years. Noninvasive 
techniques of quantification of the iron burden using magnetic resonance 
imaging (MRI) have been validated. Using MRI and echocardiography to 
monitor cardiac systems, in particular the cardiac functions that are closely 
associated with iron overload-related complications and mortality, proved to 
be practical. Our increased understanding of cardiac pathophysiology and 
our improved ability to detect at-risk populations are yielding improved 
outcomes and reduced morbidity in these reported patients. The improve-
ment in cardiac function that can be observed during L1 therapy may 
have several mechanisms. Due to its tiny size and physicochemical char-
acteristics, it can readily penetrate iron-loaded myocytes where it may 
exert anti oxidant activity or bind the excess iron and carry it out of the 
cell into the circulation where it is excreted, mainly in the urine. In addition, 
L1’s cardioprotective effects may be related to its ability to mobilize citrate-
bound iron or other forms of nontransferrin-bound iron. We have continued 
to explore the use of readily available bedside tools, such as echocardio-
grams and biochemical markers of cardiac dysfunction, to monitor tha-
lassemia patients with cardiac complications. Herein, the literature and 
our own studies/findings are summarized. L1 chelation was found to have 
marginal benefits in increasing cardiac function and reducing cardiac iron 
accumulation. [Tzu Chi Med J 2007;19(4):192–199]
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1. Introduction
Heart failure due to iron overload can develop 
either as a result of excess dietary absorption or 
from repeated blood transfusions. The most striking 
model of cardiac iron overload is seen in thalassemia 
major (TM), in which heart failure remains a major 
cause of death, greatly exceeding deaths from infec-
tion and liver disease [1]. Despite the worldwide 
introduction of the iron chelating agent deferoxam-
ine (DFO) more than 40 years ago, 50% of patients 
still die before the age of 35 years [2]. This high mor-
tality is partly due to difficulties with DFO admini-
stration. This drug requires long subcutaneous or 
intravenous infusions at least 4 days a week; com-
pliance with treatment is inadequate in many cases. 
The need for an effective alternative approach with 
an oral iron chelator has long been acknowledged 
[3] and medium-term results from prospective trials 
of the oral chelator deferi prone (L1) seem promising 
[4–6]. However, the long-term effectiveness of this 
drug has been questioned because liver iron content 
is high in some patients [7,8]. Recent studies [9,10] 
have suggested that L1 pro vides greater cardiac 
protection against iron-induced heart disease than 
DFO. The objective of iron chelation therapy is to 
prevent lethal cardiac complications from myocar-
dial iron deposition. Myocardial iron and ventricular 
function should also be taken into account when 
assessing the effectiveness of chelating agents. 
Magnetic resonance imaging (MRI) techniques have 
assessed both myocardial iron and ventricular func-
tion in these reports [11]. The present article aims 
to summarize the information from the literature 
and our own studies. Only the most profound and 
relevant data/findings from various studies on the 
efficacy of DFO and/or L1 on thalassemic cardiomy-
opathy were considered eligible for inclusion in the 
analysis. Here, we also review previously published 
data and find ings from our own studies on the same 
topic from 1999 to the present. All of these were 
focused especially on the issues of: (a) the effects 
of L1 and DFO on the heart; and (b) evidence and 
possible mechanisms of how L1 prevents cardio-
toxicity. In the final section, potential future strate-
gies for cardiomyopathy are discussed.
2. Natural history of hypertransfusion
Patients remain well for many years; symptoms are 
typically absent for < 100 units of blood transfused 
and rare until over 200 units. Cardiac arrhythmias 
are often one of the earliest signs, ranging from iso-
lated premature atrial and ventricular beats to com-
plex sustained arrhythmias. Electrocardiogram (ECG) 
changes include conduction defects, generalized 
slowing, repo lariza tion abnormalities and ventricu-
lar hypertrophy [12]. Ventricular function is typically 
normal until physical symptoms of congestive heart 
failure are noted. Stress imaging revealed a popu-
lation of “subclinical patients”. Clinical degeneration 
from the onset of clinical symptoms or ventricular 
function abnormalities was short, often less than 
6 months [13].
3.  Effect of L1 and DFO on the 
heart
Cardiac decompensation is less precipitous than 
in the unchelated state but depressed ventricu-
lar function carries a very poor prognosis. Rhythm 
disturbances are often still the earliest sign [12]. 
Both arrhythmias and cardiac dysfunction are revers-
ible with continuous DFO therapy but relapse is 
common unless prolonged therapy is maintained. 
Some patients die from iron cardiomyopathy despite 
apparently “adequate” iron chelation of ferritin and 
liver iron. Both DFO and L1 have demonstrated their 
ability to normalize cardiac function in patients 
with iron-induced cardiac disease. The improvement 
in cardiac function that can be observed during con-
tinuous intravenous DFO infusions in patients with 
iron-induced cardiac failure is limited in its removal 
of excess myocardial iron because DFO’s molecu-
lar size argues against meaningful cellular penetra-
tion [14]. Studies of cardiac iron overload in animal 
models have documented the limited ability of DFO 
to remove cardiac iron. A possible explanation for 
the beneficial effect of DFO is that it may be related 
to extracellular events, such as the decline in the 
plasma concentration of nontransferrin-bound iron 
(NTBI), which has been reported to occur during 
DFO administration. The improvement in cardiac 
function that can be observed during L1 therapy 
may have several mechanisms. Its tiny size and 
physicochemical characteristics mean that it can 
readily penetrate iron-loaded myocytes, where it may 
exert antioxidant activity or bind the excess iron 
and carry it out of the cell into the circulation where 
it is excreted, mainly in the urine. In addition, L1’s 
cardioprotective effects may be related to its abil-
ity to mobilize citrate-bound iron or other forms of 
NTBI. The need to maintain continuous levels of chela-
tors in the plasma in order to decrease cardiac injury 
by toxic species of iron may explain, in part, the dif-
ferent cardiac protective effects observed between 
continuous 24-hour infusion and the standard regi-
men of DFO. This need to maintain continuous blood 
levels of chelators could also explain the difference 
in cardioprotection observed between standard 
subcutaneous DFO administration and uninterrupted 
L1 therapy.
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4. Assessment of cardiac iron
4.1. Serum ferritin
Serum ferritin values have been the most reliable 
method available for prediction of iron-induced car-
diac damage. It is a relatively easy test to perform 
and does more than simply provide an indication of 
body iron load: several studies have shown a corre-
lation between serum ferritin level and cardiac mor-
tality in thalassemia patients [15–17]. Two recent 
trials, both exceeding 10 years, have unequivocally 
demonstrated that effective long-term use of DFO in 
TM is associated with long-term survival that is free 
of the complications of iron overload [18,19]. Both 
studies identified the magnitude of the body iron 
burden as the principal determination of clinical out-
come. One trial used serum ferritin levels to evaluate 
iron loading [18]. Over the follow-up period, patients 
with serum ferritin concentrations < 2500 μg/L had 
an estimated cardiac disease-free survival of 91% 
after 15 years. In contrast, in patients with serum 
ferritin concentrations > 2500 μg/L, estimated car-
diac disease-free survival was < 20% after 15 years. 
However, serum ferritin is an acute phase reactant, 
so its levels can be influenced by other factors, such 
as inflammatory processes, infection and chronic 
disease. Thus, single measurements of serum ferritin 
must be interpreted with caution [20]. Furthermore, 
there is little evidence demonstrating that serum 
ferritin levels correlate with cardiac function, as deter-
mined by left ventricular ejection fraction (LVEF), or 
with cardiac load, as assessed by cardiac T2 or T2* 
values [11,13,21–23].
4.2. Liver iron
The liver is the major site of iron storage in iron over-
load, accounting for more than 70% of body iron 
stores [24,25]. However, in contrast to the situation 
with serum ferritin levels, there is little evidence for 
the value of liver iron concentrations as a predictor 
of myocardial iron load or of iron-induced cardiac dis-
ease in patients undergoing chelation therapy [21].
4.3. Cardiac imaging (echography, T2 and 
T2* MRI) [11,13,26]
Cardiac performance was monitored by ECGs, which 
included B-mode, M-mode and flow Doppler investi-
gations, as determined by LVEF, etc.
The MRI T2* gradient echo technique involves 
measuring the decay in signal intensity (SI) as the 
echo time of the images is progressively increased. 
The rate of decay is strongly enhanced in the presence 
of iron deposition: increased iron levels cause 
reduced T2* values. Similarly, the extent of cardiac 
iron depositions by T2 was assessed by SI in MRI, 
which was defined by comparing the image signal to 
that of the paraspinous muscle on the same section. 
The MRI sequence was spino-echo T2-weighted in the 
axial plane. No contrast medium was given. A car-
diac T2* of less than 20 ms indicates iron overload. 
Below this value, there is a progressive and signifi-
cant decline in LVEF (r = 0.61; p < 0.0001). Based 
on this relationship, T2* values can be used as a 
guide to the level of cardiac risk (e.g. 0–10 ms = high 
risk; 10–20 ms = intermediate risk; 20 + ms = low risk). 
Apart from iron overload, no other clinical scenarios 
have been found that decrease cardiac T2* below 
20 ms. Importantly, T2* studies also showed that there 
was no significant correlation between myocardial T2* 
and liver T2*, or between myocardial T2* and the 
“traditional” measures of body iron load of serum 
ferritin and liver iron levels. It, therefore, seems rea-
sonable to conclude that myocardial iron content 
cannot be reliably predicted from serum ferritin or 
liver iron levels, and that T2* is the only currently 
available technology that provides a reliable assess-
ment of heart iron load.
5.  Summary of literature regarding 
treatment for myocardial 
siderosis
The primary goal of chelation therapy is to prevent 
iron-induced organ damage and premature death. 
Implicit in this goal is the imperative to remove iron 
effectively from the heart (target lethal organ) in tha-
lassemia [26]. DFO can improve survival and delay 
the complications of iron overload [16]. Standard ther-
apy involves subcutaneous infusion of 20–40 mg/kg/
day over 8–24 hours, 5–7 days per week [27] and 
is usually initiated in children after the first 10–20 
blood transfusions. Prior to the availability of DFO, 
iron-induced myocardial disease was invariably fatal 
[28]. Continuous 24-hour parenteral infusion of DFO 
aimed at removing cardiac iron can reverse arrhythmias 
and congestive heart failure in many patients [29]. 
Anderson et al [14] followed thalassemia patients com-
mencing intravenous DFO for iron-induced cardiomy-
opathy during a 12-month period. The data confirms 
that siderotic heart failure is often reversible with 
intravenous iron chelation by DFO. Myocardial T2* 
improves in concert with left ventricular volumes and 
function during recovery, although iron clearance 
from the heart is considerably slower than from the 
liver. In another retrospective study, Anderson et al 
[9] (Table 1) compared myocardial iron content and 
cardiac function in 15 patients receiving long-term 
L1 treatment with 30 matched controls on long-term 
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treatment with DFO. MRI T2* was used to measure 
cardiac iron. The researchers found that the L1 group 
had significantly less myocardial iron than the DFO-
treated group (p = 0.02). The odds ratio for excess 
myocardial iron with DFO was 5.5 (95% confidence 
interval, 1.2–28.8). Cardiac function was also better 
in the L1 group: this group had a higher mean LVEF 
(p = 0.004) and less left ventricle dilatation in systole 
(p = 0.03) and diastole (p = 0.01) than the DFO group. 
The same results were recently confirmed in a larger, 
prospective, randomized controlled trial by Pennell 
et al [30] (Table 1). In this study, 61 patients pre-
viously treated with DFO were randomized to be 
maintained on DFO (43 mg/kg for 5.7 days/week) 
or switched to L1 (92 mg/kg/day). During the 1-year 
period of the study, compliance was similar in the two 
groups (93% vs. 94%, respectively; p = 0.023). There 
was significantly greater improvement in myocardial 
T2* for patients receiving L1 than those receiving 
DFO (27% vs. 13%; p = 0.023). LVEF also increased 
more significantly in the L1 group (3.1% vs. 0.3%; 
p = 0.0034). Baseline serum ferritin level was not sig-
nificantly predictive of the improvement in T2*. The 
prospective trials demonstrating superior efficacy 
in treating cardiac siderosis and better outcome for 
LVEF have received some support from outcome 
studies looking at survival and clinical complications. 
The first survival data comparing L1 and DFO was 
reported from a recent retrospective study by Piga 
et al [10] (Table 1). This study compared records of 
54 patients treated with L1 with that of 75 patients 
treated with DFO for an average of 6 years. All patients 
had been previously treated with DFO. The study found 
that cardiac disease-free survival was signi ficantly better 
in the L1 group over the course of 5 years (p = 0.003). 
Cardiac dysfunction was diagnosed in two (4%) of the 
Table 1 — Studies that compare cardiac parameters from different chelation therapy styles
  
Length
 Chelation SIR of T2
a or T2*b MRI
Order Patients, 
of study
 treatment (estimation; a: 0.92 ±  
Conclusions
[Ref] n 
(mo)
 & dose 0.12, b: > 20 ms) LVEF (%)
   (mg/kg/d) Initial Final Initial Final
1 [9]  30 68.4 DFO (37.4) ND 11.4 ND  63 (± 6.9) Excess myocardial iron 
     (7.0–25.0)b     significantly less common in the 
  15  L1 (80.5) ND  34.0* ND 70* (± 6.5)  L1 group
     (18.0–56.0)b
2 [10]  75 73 DFO (20–50) ND    L1 group had significantly greater 
  54  L1 (25–100)      cardiac disease-free survival over 
         5 yr (p = 0.003)
3 [30]  32 12 DFO (43) 13.3b  15.0b 68.4 68.5 L1 had superior efficacy in 
         reducing cardiac iron over 12 mo 
  29  L1 (92) 13.0b   16.5*b 69.7 73*  assessed by T2* and LVEF
4 [31] 359 108 DFO (30–50) ND    L1 group had 0% cardiac events 
 157  L1 (75)      over 9 yr vs. 14.5% with DFO 
         group
5 [22]  10 36 DFO (45.4) 0.68 (± 0.23)a 0.69 (± 0.18)a 63.3 (± 6.3) 64.6 (± 7.0) - L1 group had a superior LVEF 
  11  L1 (73.8) 0.67 (± 0.21)a 0.87* (± 0.17)a 58.6 (± 6.8) 65.2* (± 7.1)   improvement
        - The improvement in LVEF was 
          proportional to the reduction in 
          cardiac iron deposition 
           (SIR T2 MRI)
6 [23] Patient 1 13 DFO (50) + 0.55a 0.88a 41 58 Combined therapy can successfully
    L1 (80)      regress severe siderosis 
 Patient 2   6 DFO (50) + 0.49a 0.85a 35 64  cardiomyopathy
    L1 (80)
7  26 28 DFO (50) 0.67 (± 0.25)a 0.68 (± 0.18)a 64.3 (± 6.1) 65.2 (± 7.1) - Combined chelation therapy 
[32,38]  57 36  L1 (75) 0.68 (± 0.24)a 0.86* (± 0.19)a 56.6 (± 6.5) 66.3* (± 6.9)   (L1 + DFO) was the most effective 
  31 24 DFO (40) + 0.62 (± 0.33)a 0.89* (± 0.21)a 52.4 (± 6.3) 70.3* (± 7.0)   against thalassemic 
    L1 (75)       cardiomyopathy
        - L1-only group was the 2nd of 3
        - DFO-only group was the 3rd of 3
8 [13]   9 132 (DFO, DFO (50) was  EPSS (DFO: 8.11 ± 3.67 to L1: 2.9 ± 0.89*) Myocardial dysfunction can be
  84; L1, 48)  switched to EPSS/LVDd (DFO: 0.19 ± 0.08 to L1: 0.06 ± 0.02*)  reversed by oral L1
    L1 (75) LA/AO (DFO: 1.27 ± 0.15 to L1: 1.10 ± 0.13*)
    since 1999
*p < 0.05, initial vs. final data. EPSS = E-point of a full opened mitral valve to septum separation (mm); LVEF = left ventricular ejection fraction; 
EPSS/LVDd = E-point to septal separation/left ventricular end-diastolic dimensions; LA/AO = left atrial dilatation was defined by the ratio between 
the left atrium dimension and the aorta diameter; a = T2 MRI; b = T2* MRI; ND = no data.
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L1-treated patients and in 15 (20%) of the DFO-
treated patients (p = 0.007).
 A recent multicenter natural history study by Borgna-
Pignatti et al [31] (Table 1) also found that cardiac dis-
ease outcome and survival were better for patients 
treated with L1 than with DFO. The study involved 359 
patients receiving DFO (30–50 mg/kg/day, 5–6 times 
per week) and 157 patients who were switched to L1 
(75 mg/kg/day, 3 times a day) at seven Italian centers 
between 31 January 1995 and 31 December 2003. 
There were a total of 52 cardiac events, including 15 
cardiac deaths, during the 9-year period. All events 
occurred in the patients treated with DFO and there 
were no cardiac events in those receiving L1. Overall, 
14.5% of the DFO patients had a cardiac event ver-
sus 0% of the L1 patients. The authors concluded 
that their epidemiological study “demonstrated a sig-
nificant difference in cardiac morbidity and mortal-
ity between thalassemia patients treated with L1 and 
those treated with DFO”.
Between January 1999 and the present, there have 
been five reports from the Pediatric Hematology 
Divi sion, China Medical University Hospital, Taichung, 
Taiwan. Four reports on β-TM patients, who received 
regular blood transfusions and various types of chela-
tion therapy, compare the incidence of iron-induced 
cardiac disease and the recovery rates in the differ-
ent treatment modalities (Table 1). The other report 
compared cardiac function differences between nor-
mal people and TM patients [12]. Our first prospective 
report [22] compared cardiac iron and LVEF over 3 years 
between 10 patients allocated to DFO (50 mg/kg/
day) at least 5 days per week and 11 patients receiv-
ing L1 (75 mg/kg/day) orally every 8 hours. Cardiac 
iron levels, estimated by SI of T2 MRI, were markedly 
improved in five of the 11 patients in the L1 group, 
whereas in the DFO group only slight improvement was 
seen in only two of the 10 patients. Mean LVEF sig-
nificantly improved in the patients receiving L1, from 
58.6 ± 6.8% to 65.2 ± 7.1%, whereas there was no 
sig nificant change in the DFO group (63.3 ± 6.3% to 
64.6 ± 7.0%). The two drugs had equivalent effects 
on serum ferritin and hepatic iron levels, again indicat-
ing that these two parameters do not reflect cardiac 
iron levels.
We reported on the successful treatment of severe 
heart failure in two patients with β-TM with combined 
therapy in 2003 [23]. The T2 MRI showed a marked 
recovery of SI in the heart, indicating a significant 
reduction of iron load in the heart (Fig. 1). Therefore, 
combined therapy of L1 and DFO has been suggested 
in patients with β-TM and cardiac complications. We 
also reported on nine patients with TM complicated 
by some degree of myocardial dysfunction in the journal 
Hemoglobin in 2006 [13]. These patients, recipients 
of > 10 years of DFO injection therapy, were switched 
from DFO to L1. Echocardiographic measures of left 
ventricular systolic, diastolic and global function were 
assessed regularly every 6 months. Global cardiac func -
tion improved significantly: E-point-to-septal separation 
(EPSS) (8.11 ± 3.67 mm vs. 2.9 ± 0.89 mm, p < 0.01), 
EPSS/left ventricle diastolic dimension (LVDd) ratio 
(0.19 ± 0.08 vs. 0.06 ± 0.02, p < 0.01) and left atrium/
aorta (LA/AO) ratio (1.27 ± 0.15 vs. 1.10 ± 0.13, 
p = 0.02) all decreased. We concluded that myocardial 
dysfunction in patients with TM can be reversed by 
regular use of oral iron chelator L1. That same year, 
we conducted a case study, enrolling 136 patients 
with transfusion-dependent TM from five medical 
centers in Taiwan [32]. Combined therapy was the 
A B
Fig. 1 — Magnetic resonance imaging of a patient’s heart: (A) before combined therapy, axial view of the heart shows 
a decrease in signal intensity (SI) in the myocardium, suggesting substantial iron deposition (between arrows); (B) 13 
months after combined therapy, marked recovery of SI suggests depletion of iron deposition (between arrows). Reprinted 
with permission from reference 23.
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most effective at reducing iron burden, as assessed 
by serum ferritin levels, SI of T2 MRI and M-mode 
echocardiography (LVEF). The L1-only group had the 
second best improvement, followed lastly by the DFO-
only group (Fig. 2). In 2004, we performed ECGs in 
39 patients with β-TM and 35 aged-matched controls 
[12]. Gender, age, heart rate, blood pressure, LVEF, 
acceleration time (AcT) of right ventricular outflow 
and right ventricular ejection time (RVET), AcT/RVET 
and the presence of tricuspid regurgitation (TR) were 
compared between the two groups. The incidence of 
TR in thalassemic patients was significantly higher 
than that in the control group (30.8% vs. 11.4%, 
p = 0.03). The incidences of splenectomy (p = 0.03), 
plate let counts (p = 0.01) and SI ratio of myocardial 
MRI (p = 0.03) in thalassemic patients with TR were 
significantly higher than in those without TR. Also, 
the AcT was shorter and AcT/RVET ratio was smaller, 
suggesting higher pulmonary pressure in the tha-
lassemic patients with TR. Occurrence of TR in 
patients with β-TM may be a consequence of cardiac 
iron deposit, thrombocytosis, splenectomy or pulmo-
nary hypertension.
6. Discussion
These studies provide strong evidence of the apparent 
superiority of L1 in preventing cardiac complications 
as the patients included are more likely to represent 
the disease population as a whole. L1 (1,2-dimethyl-
3-hydroxypyrid-4-one) is an orally active chelator from 
the bidentate hydroxypyridinones family. It was syn-
thesized in 1982 but development did not follow a 
systematic design. Toxic effects include arthropathy, 
neutropenia and agranulocytosis, which demand close 
monitoring. In comparison with standard DFO treat-
ment, doses of L1 of 75 mg/kg of body weight/day give 
comparable urinary iron excretion levels. The effect 
on liver iron concentration may vary among patients. 
Several aspects of its safety and efficacy, as well as 
development, have been matters of serious discussions 
and controversies. The basic molecular mechanism of 
thalassemic syndrome is the reduced synthesis of the 
β-globin chains [33]. The consequences of the result-
ing chronic anemia are common, and include growth 
retardation, bone marrow expansion, extramedullary 
hematopoiesis, splenomegaly, increased intestinal 
iron absorption, susceptibility to infections and hyper-
coagulability [33,34]. What differentiates the major 
and intermediate forms of β-thalassemia is the sever-
ity of the clinical phenotype, which depends on a par-
ticularly heterogeneous molecular background and is 
mainly determined by the balance between α- and 
β-globin chains and the quantity of γ-globin chains [33]. 
The diverse clinical severity has led, in turn, to totally 
different therapeutic approaches. In these studies, TM 
patients have universally been on an intensive trans-
fusion regimen that has maintained their hemoglobin 
level close to normal, hence allowing adequate tissue 
oxygen delivery. Before the introduction of regular 
treatment for TM, most patients died of high-output 
heart failure, usually by the end of the first decade of 
life. Regular therapy, which has been gradually intro-
duced, modified the form and severity of thalassemia 
heart disease. At the same time, the heterogeneous 
cardiac outcome reflected the treatment variability 
with respect to frequency of transfusions and inten-
sity of iron chelation. Left ventricular dysfunction was 
the only notable abnormality in TM and, in accordance 
with existing knowledge, was the cause of congestive 
heart failure in these patients. In TM patients with evi-
dent heart disease, end-systolic stress and relative 
wall thickness were affected following left ventricular 
dysfunction. Systolic left ventricular dysfunction, how-
ever, was not observed in patients less than 23 years 
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Fig. 2 — Difference in effectiveness of different chelation therapy styles in: (A) left ventricular ejection fraction (LVEF); 
(B) signal intensity of T2 magnetic resonance imaging. Deferiprone (L1) + deferoxamine (DFO) was most effective, L1-only 
was the second most effective, and DFO-only was the least effective. Reprinted with permission from reference 38.
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old. Chelation therapy reduces pulmonary and cardiac 
iron deposition, and their contribution to the eleva-
tion of pulmonary vascular resistance [35]. However, 
aside from restricting the negative effects of hemolysis 
on nitric oxide and arginine availability, regular trans-
fusion therapy also prevents chronic tissue hypoxia 
and its consequences that have been implicated in 
the pathogenesis of pulmonary hypertension [35,36]. 
Cardiac death due to iron overload still accounts for 
two thirds of mortality due to TM, despite the availabil-
ity of DFO for almost three decades. Without adequate 
iron chelation therapy, myocardial siderosis develops 
within the first decade of life and leads, inexorably, 
to heart failure. Monitoring of cardiac involvement in 
iron overload presents major challenges, since neither 
serum ferritin nor liver iron levels are reliable indica-
tors of cardiac iron, and clinical symptoms only appear 
late in the course of the disease. Measurement of 
heart iron load by MRI T2 and T2* technique is provid-
ing useful insights into both the course of myocardial 
siderosis and the relative benefits of iron chelators. 
However, substantial evidence continues to accumu-
late, which is independent of treatment compliance, 
that the oral iron chelator L1 possesses cardiac ben-
efits when compared with DFO [30,31]. The available 
data appear to demonstrate that L1 may have greater 
cardiac benefits than DFO. A possible explanation for 
the apparent superiority of L1 over DFO in removing 
excess cardiac iron is that L1 has a superior ability to 
penetrate myocardial cells due to its lower molecular 
weight, neutral charge and greater lipophilicity [37].
DFO is administered parenterally and L1 is an oral 
therapy, so it is important to consider whether the 
apparent superiority of L1 in controlling cardiac iron 
might be due to superior compliance alone. This does 
not appear to be the case. Anderson et al [9] found 
excess cardiac iron, as assessed by a T2* of < 20 ms, 
in DFO-treated patients who appeared to be comply-
ing with their drug regimen. In the study by Piga et al 
[10], in which cardiac disease-free survival was supe-
rior in the L1 group, the compliance rates were not 
significantly different for L1 and DFO. The authors 
speculated that the good compliance rate in the DFO 
group was due to the “regular and greater intensive 
attention” given to chelation therapy at the center. 
The same findings were also noted in our own studies 
[13,30,31] (Table 1). So, compliance was not the only 
variable but unarguably increased the treatments’ 
effectiveness.
In a previous International Conference on Oral 
Chelation (ICOC) symposium [38], the ICOC commit-
tee recommended the following combination dose 
pro tocol for a universally effective chelation therapy 
in thalassemia patients: L1 at 80–110 mg/kg/day 
during the day and DFO 40–60 mg/kg/day, at least 
3 days per week, during the night. The combination 
therapy can also be carried out in a simultaneous or 
sequential way as follows: DFO 20–50 mg/kg/day for 
2–6 days (depending on the degree of iron overload) 
and L1 70–80 mg/kg/day for 7 days a week [39].
Results of large and controlled studies in humans 
became available in the 1990s and this allowed the 
approval of L1 in many countries, often as a second-
line treatment for iron overload, although some put it 
in the first line in the late 1990s and 2000s. In recent 
years, data from several trials provided new evidence 
for the efficacy of L1 in the treatment of iron over-
load and its tolerability profile. Unfortunately, this 
drug has become an example, rightly or wrongly, of 
how difficult the academic–industry relationship can 
be today. Up to now (January 2007), L1 has not been 
approved in the United States or Canada.
7. Future strategies
Many clinical challenges remain. Cardiac complica-
tions still start too early in a patient’s life and an ideal 
management strategy to prevent cardiac siderosis is 
still unclear. The role of the prophylactic use of L1, 
alone or in combination, needs to be determined. 
Combined therapy of L1 and DFO does not show any 
increased incidence of toxicity, and may be the best 
method in many transfusion-dependent patients for 
achieving satisfactory iron chelation therapy with good 
long-term patient compliance, especially in patients 
with cardiac complications [31]. It is possible that 
more frequent doses of DFO than those stated in the 
previously reported data, combined with L1 intake, 
will greatly augment the efficacy of this combined 
therapy. The optimal timing of MRI T2 or T2* assess-
ments and the frequency of follow-up scans is still 
empirical. The role of conventional cardiovascular ther-
apies, such as angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blockers and β-blockers, 
also needs to be fully defined. As one monograph has 
shown, the clinical evidence of an iron chelator’s car-
diac benefits takes years to demonstrate, and cur-
rently there exists only preliminary data on the ability 
of deferasirox to remove iron from the heart [40].
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